4 December 2020 - The U.S. FDA has approved Saxenda (liraglutide) for chronic weight management among patients aged 12 and older who are obese, as defined by specific body mass index cut-offs for age and sex that correspond to a BMI 30 kg/m2 or higher for adults, and who weigh more than 60 kg (132 pounds). 

Saxenda is an adjunct (additional therapy) to a reduced-calorie diet and greater physical activity.

Read FDA press release